CORE--CLINICAL BIOCHEMISTRY FACILITY

核心--临床生化设施

• 批准号: 6300126
• 负责人: JOHN P RICHIE
• 金额: $ 26.2万
• 依托单位: INSTITUTE FOR CANCER PREVENTION
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-22 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6300126
• 关键词: animal tissue; biochemistry; biomedical facility; chemical registry /resource; chemical standardization; clinical chemistry; evaluation /testing; human tissue; method development; occupational health /safety; radioimmunoassay

The purpose of the Clinical Biochemistry Facility is to provide quality- controlled analyses for clinical chemistry and biochemical epidemiology to CCSG-supported AHF scientists. The facility is staffed by a facility head, John P. Richie, Jr., Ph.D. a lab supervisor, Steven Colosimo, M.S. a clinical chemist, Tara Bonanno, B.S. and a clinical coordinator, Julie Heidbrink-Fallon, B.A. The major resources of the facility include a Johnson & Johnson Vitros 500 Mainframe Clinical Chemistry Analyzer, several portable clinical chemistry analyzers Dynatech 5000 96 well plate reader with Biolinx software, scintillation counters, HPLCs, GC, autoanalyzers and a automate hematological analyzer. The facility offers routine clinical chemistry assays and immunoassays as well as specialized biochemistry and biomarker tests using a charge-back mechanism. In addition the facility is involved in biomarker development for use in large-scale human studies. This facility provides services to all of the CCSG-supported programs as well as to non-programmatically aligned programs within AHF and at other facilities. Approximately 10-15 peer- funded investigators at AHF as well as 12-18 external scientists make use of the facility each year for a total of about 6,000 to 10,000 samples assayed per year. Over the past year, 63% of the total use of the facility was by peer-reviewed NIH-or ACS-funded projects. In the present funding cycle, we plan to expand the capabilities of the facility to include hematological analyses and human studies underway and planned within the AHFCC as well as in support of ongoing studies within the AHFCC as well as in support of ongoing studies within the Research Animal Facility. In addition, to assist in the implementation of human investigation we plan to provide expertise in clinical coordination and biological sample collection and banking. This new expertise within the AHFCC is essential for the implementation of human studies, particularly at the Naylor Dana Institute where an increasing demand is clearly evident. Of particular importance, the facility will provide assistance with confidentiality issues especially in human studies involving DNA analysis.

临床生物化学设施的目的是提供质量 - 对临床化学和生化流行病学的控制分析 CCSG支持的AHF科学家。该设施由设施负责人组成 小约翰·P·里奇（John P. Richie）博士实验室主管，史蒂文·科洛西莫（Steven Colosimo），硕士一个 临床化学家，塔拉·邦纳诺（Tara Bonanno），学士学位还有临床协调员朱莉 Heidbrink-Fallon，学士该设施的主要资源包括 Johnson＆Johnson Vitros 500大型机临床化学分析仪， 几个便携式临床化学分析仪Dynatech 5000 96井板 具有Biolinx软件，闪烁计数器，HPLC，GC，GC， 自动分析仪和自动血液学分析仪。该设施提供了 常规的临床化学分析和免疫测定以及专业 使用电荷机制进行生物化学和生物标志物测试。在 此外，该设施参与了生物标志物开发 大型人类研究。该设施为所有人提供服务 CCSG支持的程序以及非编程的对齐 AHF和其他设施中的程序。大约10-15个同伴 AHF的资助研究人员以及12-18位外部科学家使用 每年的设施中，总计约6,000至10,000个样本 每年分析。在过去的一年中，该设施总使用的63％ 是通过同行评审的NIH-或ACS资助的项目。在目前的资金中 循环，我们计划扩大设施的功能，包括 血液学分析和人类研究正在进行中，并计划在 AHFCC以及支持AHFCC内正在进行的研究以及 支持研究动物设施中正在进行的研究。在 此外，为了协助实施人类调查，我们计划 提供临床协调和生物样本方面的专业知识 收集和银行业务。 AHFCC中的新专业知识至关重要 为了实施人类研究，特别是在Naylor Dana 显然需求不断增长的研究所。特别 重要的是，该设施将提供机密性的帮助 尤其是在涉及DNA分析的人类研究中的问题。